Kenmotsu, Hirotsugu http://orcid.org/0000-0001-7853-5206
Ohde, Yasuhisa
Wakuda, Kazushige
Nakashima, Kazuhisa
Omori, Shota
Ono, Akira
Naito, Tateaki
Murakami, Haruyasu
Kojima, Hideaki
Takahashi, Shoji
Isaka, Mitsuhiro
Endo, Masahiro
Takahashi, Toshiaki
Funding for this research was provided by:
Japan Agency for Medical Research and Development
Article History
Received: 6 March 2017
Accepted: 21 July 2017
First Online: 31 July 2017
Compliance with ethical standards
:
: This study was funded by the Japan Agency for Medical Research and Development (Grant No. 16lk0201005h0005).
: Hirotsugu Kenmotsu has received grants and personal fees from AstraZeneca K.K., grants and personal fees from Chugai Pharmaceutical Co, Ltd., grants and personal fees from Boeringer Ingelheim, personal fees from Ono Pharmaceutical Co, Ltd., personal fees from Bristol-Myers K.K, grants and personal fees from Taiho Pharmaceutical Co, Ltd., personal fees from Eli Lilly K.K, personal fees from Kyowa Hakko Kirin Co., Ltd. Kazushige Wakuda has received personal fees from Eli Lilly K.K, Chugai Pharmaceutical Co, Ltd., Ono Pharmaceutical Co, Ltd., Taiho Pharmaceutical Co, Ltd., Boeringer Ingelheim. Kazuhisa Nakashima has received personal fees from Ono Pharmaceutical Co, Ltd., Taiho Pharmaceutical Co, Ltd. Shota Omori has received personal fees from AstraZeneca K.K., Chugai Pharmaceutical Co, Ltd., Ono Pharmaceutical Co, Ltd., Taiho Pharmaceutical Co, Ltd., Boeringer Ingelheim. Akira Ono has received honoraria from Chugai Pharma, Taiho Pharmaceutical and research funding to our institution from Takeda Pharmaceuticals and Taiho Pharmaceutical Co, Ltd. Tateaki Nito has received personal fees from Ono Pharmaceutical Co, Ltd. Haruyasu Murakami has received personal fees from Astrazeneca, personal fees from Chugai pharma, personal fees from Novartis, personal fees from Boehringer Ingelheim, personal fees from Phizer, personal fees from Taiho Pharmaceutical, personal fees from Lilly Japan, personal fees from Ono Pharmaceutical, personal fees from Bristol-Myers Squibb Japan, personal fees from Teijin Pharma, personal fees from Clovis Oncology, personal fees from Nippon Kayaku, other from Astellas Pharma. Masahiro Endo has received personal fees from Ono Pharmaceutical Co, Ltd. Toshiaki Takahashi has received grants from the Ministry of Health, Labour and Welfare of Japan, during the conduct of the study; grants and personal fees from AstraZeneca KK, personal fees from Boehringer Ingelheim, grants and personal fees from Pfizer Japan Inc., grants and personal fees from Eli Lilly Japan K.K., grants and personal fees from Chugai PHARMACEUTICAL CO., LTD., grants and personal fees from ONO PHARMACEUTICAL CO., LTD., grants and personal fees from Takeda Pharmaceutical Company LTD., grants from TAIHO PHARMACEUTICAL CO., LTD., grants from MSD K.K. The remaining authors declare that they have no conflict of interest.
: For this type of study, formal consent is not required.